Evidence map›Paper›PMID 37261290›Full record

ArticleFrontiers in pharmacology2023

Long-term economic evaluation of the recombinant

Sha Diao, Zheng Liu, Dan Liu, Xiao Cheng, Linan Zeng, Xue-Feng Jiao, Zhe Chen, Xiaofeng Ni, Siyi He, Bin Wu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Commentary: RecombinantFrontiers in public health · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Sha DiaoEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Zheng LiuEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Dan LiuEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Xiao ChengEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Linan ZengEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Xue-Feng JiaoEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Zhe ChenEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Xiaofeng NiEvidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Siyi HeDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Bin WuDepartment of Pharmacy, Renji Hospital Affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Deying KangChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Chaomin WanKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Rongsheng ZhaoDepartment of Pharmacy, Peking University Third Hospital, Beijing, China.
Huiqing WangMedical Simulation Centre, West China Second University Hospital, Sichuan University, Chengdu, China.
Lingli ZhangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
West China Second University Hospital of Sichuan University · CNNational Medical Products Administration · CNSichuan University · CNPeking University Third Hospital · CNRenji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cost-utilitydecision tree-markov modelMycobacterium tuberculosis infectionpurified protein derivative of tuberculin (TB-PPD)recombinant Mycobacterium tuberculosis fusion protein (EC)

Identifiers

PMID37261290
PMCPMC10228647
OpenAlexW4376646175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.